Alqam Mona L, Jones Brian C, Hitchcock Thomas M
Dr. Alqam is with Medical Affairs and Clinical Development at Crown Laboratories in Dallas, Texas.
Dr. Jones is with Research and Development at Crown Laboratories in Dallas, Texas.
J Clin Aesthet Dermatol. 2025 May 1;18(5):44-53.
For individuals with acne-prone skin, identifying a topical regimen that does not lead to progression of their inflammatory issues often poses a challenge. A topical skin probiotic regimen containing a specific strain of subspecies , XYCM42, has been shown to be beneficial in improving skin health and appearance in individuals with generally healthy skin, but the use of the skin probiotic has not been sufficiently assessed in individuals with acne-prone skin.
The purpose of this study was to evaluate the safety and efficacy of daily application of a topical skin biome care regimen containing a living subsp. derivative strain, XYCM42, its ferment, and adjunct topicals in individuals with acne-prone skin.
This eight-week study was conducted at five locations and included 136 total participants. At baseline, Week 1, Week 4, and Week 8, subjects completed product questionnaires and symptom severity surveys. Of the study subjects, 20 were enrolled for clinical efficacy evaluation at all timepoints. Clinical assessments included blemish lesion counts, Investigator's Global Assessment (IGA) of acne lesion severity, and clinical grading of skin cosmetic and safety parameters.
As early as Week 1 of regimen application, clinical observations demonstrated statistically significant improvements in acne severity scores, with no subjects reporting increased or worsened acne during the study. By Week 4, subjects showed significant changes in nearly all skin cosmetic parameters assessed, including skin texture, clarity, tone, fine wrinkling, undereye dark circles, dryness, and erythema. Lesion counts were significantly reduced from baseline at all timepoints, with 100 percent of subjects experiencing fewer non-inflammatory lesions and 70 percent and 30 percent with fewer papule and pustule inflammatory lesions, respectively, by the end of the study. No adverse events were reported.
This at-home use study demonstrates that use of the XYCM42-based topical skin biome care regimen is both safe and appropriate for individuals with acne-prone skin. More broadly, the outcomes of this study provide further support toward the beneficial and commensal nature of subsp. in promoting skin health.
对于易长痤疮的个体而言，确定一种不会导致其炎症问题加重的局部治疗方案往往颇具挑战。一种含有特定亚种XYCM42菌株的局部皮肤益生菌治疗方案，已被证明对改善皮肤总体健康的个体的皮肤健康和外观有益，但该皮肤益生菌在易长痤疮的个体中的使用尚未得到充分评估。
本研究旨在评估每日应用一种含有活的亚种衍生菌株XYCM42及其发酵产物和辅助局部用药的局部皮肤生物群落护理方案对易长痤疮个体的安全性和有效性。
这项为期八周的研究在五个地点进行，共有136名参与者。在基线、第1周、第4周和第8周，受试者完成产品问卷和症状严重程度调查。在所有时间点，有20名研究对象参与临床疗效评估。临床评估包括瑕疵皮损计数、研究者对痤疮皮损严重程度的整体评估（IGA）以及皮肤美容和安全参数的临床分级。
早在治疗方案应用的第1周，临床观察就显示痤疮严重程度评分有统计学意义的改善，在研究期间没有受试者报告痤疮加重或恶化。到第4周时，受试者在几乎所有评估的皮肤美容参数上都有显著变化，包括皮肤质地、清晰度、色调、细纹、眼周黑眼圈、干燥和红斑。在所有时间点，皮损计数均较基线显著减少，到研究结束时，100%的受试者非炎性皮损减少，70%和30%的受试者丘疹和脓疱炎性皮损减少。未报告不良事件。
这项居家使用研究表明，基于XYCM42的局部皮肤生物群落护理方案对易长痤疮的个体既安全又适用。更广泛地说，本研究结果为亚种在促进皮肤健康方面的有益和共生性质提供了进一步支持。
